Discontinuing denosumab after 1 year of treatment quickly leads to reversal of its inhibitory effect on bone turnover markers and improvements in bone mineral density among people using glucocorticoids for rheumatoid arthritis, research shows.
In patients with rheumatoid arthritis, low-dose glucocorticoids are associated with an increased risk for vertebral fracture, but not with overall or non-vertebral fractures, show findings from a UK-based retrospective cohort study.
Less than half of patients with polymyalgia rheumatica are prescribed medications for osteoporosis, despite clinical guidelines recommending bone protection for those on long-term glucocorticoid treatment, research suggests.
Concomitant use of oral glucocorticoids and proton pump inhibitors significantly increases the risk for osteoporotic fractures in people with rheumatoid arthritis, with the combined effect greater than that for each drug class alone, research suggests.
Romosozumab and other sclerostin inhibitors may increase cardiovascular risk, suggests evidence from a meta-analysis of randomized trials and a study of genetic variants that mimic pharmacologic inhibition of sclerostin.